Preparing clinical pharmacy scientists for careers in clinical/ translational research

Can we meet the challenge?: ACCP research affairs committee commentary

Robert Parker, Vicki Ellingrod, Joseph T. Dipiro, Jerry L. Bauman, Robert A. Blouin, Lynda S. Welage

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Developing clinical pharmacists' research skills and their ability to compete for extramural funding is an important component of the American College of Clinical Pharmacy's (ACCP) vision for pharmacists to play a prominent role in generating the new knowledge used to guide patient pharmacotherapy. Given the recent emphasis on clinical/translational research at the National Institutes of Health (NIH) and the key role of drug therapy in the management of many diseases, there is an unprecedented opportunity for the profession to contribute to this enterprise. A crucial question facing the profession is whether we can generate enough appropriately trained scientists to take advantage of these opportunities to generate the new knowledge to advance drug therapy. Since the 2009 publication of the ACCP Research Affairs Committee editorial recommending the Ph.D. degree (as opposed to fellowship training) as the optimal method for preparing pharmacists as clinical/translational scientists, significant changes have occurred in the economic, professional, political, and research environments. As a result, the 2012 ACCP Research Affairs Committee was charged with reexamining the college's position on training clinical pharmacy scientists in the context of these substantial environmental changes. In this commentary, the potential impact of these changes on opportunities for pharmacists in clinical/translational research are discussed as are strategies for ACCP, colleges of pharmacy, and the profession to increase the number and impact of clinical pharmacy scientists. Failure of our profession to take advantage of these opportunities risks our ability to contribute substantively to the biomedical research enterprise and ultimately improve the pharmacotherapy of our patients.

Original languageEnglish (US)
JournalPharmacotherapy
Volume33
Issue number12
DOIs
StatePublished - Jan 1 2013

Fingerprint

Translational Medical Research
Pharmacists
Aptitude
Drug Therapy
Medication Therapy Management
National Institutes of Health (U.S.)
Research
Publications
Biomedical Research
Economics
Pharmacy Research

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Preparing clinical pharmacy scientists for careers in clinical/ translational research : Can we meet the challenge?: ACCP research affairs committee commentary. / Parker, Robert; Ellingrod, Vicki; Dipiro, Joseph T.; Bauman, Jerry L.; Blouin, Robert A.; Welage, Lynda S.

In: Pharmacotherapy, Vol. 33, No. 12, 01.01.2013.

Research output: Contribution to journalReview article

Parker, Robert ; Ellingrod, Vicki ; Dipiro, Joseph T. ; Bauman, Jerry L. ; Blouin, Robert A. ; Welage, Lynda S. / Preparing clinical pharmacy scientists for careers in clinical/ translational research : Can we meet the challenge?: ACCP research affairs committee commentary. In: Pharmacotherapy. 2013 ; Vol. 33, No. 12.
@article{6418935b2500420c84d58ee7dde5ff6e,
title = "Preparing clinical pharmacy scientists for careers in clinical/ translational research: Can we meet the challenge?: ACCP research affairs committee commentary",
abstract = "Developing clinical pharmacists' research skills and their ability to compete for extramural funding is an important component of the American College of Clinical Pharmacy's (ACCP) vision for pharmacists to play a prominent role in generating the new knowledge used to guide patient pharmacotherapy. Given the recent emphasis on clinical/translational research at the National Institutes of Health (NIH) and the key role of drug therapy in the management of many diseases, there is an unprecedented opportunity for the profession to contribute to this enterprise. A crucial question facing the profession is whether we can generate enough appropriately trained scientists to take advantage of these opportunities to generate the new knowledge to advance drug therapy. Since the 2009 publication of the ACCP Research Affairs Committee editorial recommending the Ph.D. degree (as opposed to fellowship training) as the optimal method for preparing pharmacists as clinical/translational scientists, significant changes have occurred in the economic, professional, political, and research environments. As a result, the 2012 ACCP Research Affairs Committee was charged with reexamining the college's position on training clinical pharmacy scientists in the context of these substantial environmental changes. In this commentary, the potential impact of these changes on opportunities for pharmacists in clinical/translational research are discussed as are strategies for ACCP, colleges of pharmacy, and the profession to increase the number and impact of clinical pharmacy scientists. Failure of our profession to take advantage of these opportunities risks our ability to contribute substantively to the biomedical research enterprise and ultimately improve the pharmacotherapy of our patients.",
author = "Robert Parker and Vicki Ellingrod and Dipiro, {Joseph T.} and Bauman, {Jerry L.} and Blouin, {Robert A.} and Welage, {Lynda S.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1002/phar.1348",
language = "English (US)",
volume = "33",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "12",

}

TY - JOUR

T1 - Preparing clinical pharmacy scientists for careers in clinical/ translational research

T2 - Can we meet the challenge?: ACCP research affairs committee commentary

AU - Parker, Robert

AU - Ellingrod, Vicki

AU - Dipiro, Joseph T.

AU - Bauman, Jerry L.

AU - Blouin, Robert A.

AU - Welage, Lynda S.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Developing clinical pharmacists' research skills and their ability to compete for extramural funding is an important component of the American College of Clinical Pharmacy's (ACCP) vision for pharmacists to play a prominent role in generating the new knowledge used to guide patient pharmacotherapy. Given the recent emphasis on clinical/translational research at the National Institutes of Health (NIH) and the key role of drug therapy in the management of many diseases, there is an unprecedented opportunity for the profession to contribute to this enterprise. A crucial question facing the profession is whether we can generate enough appropriately trained scientists to take advantage of these opportunities to generate the new knowledge to advance drug therapy. Since the 2009 publication of the ACCP Research Affairs Committee editorial recommending the Ph.D. degree (as opposed to fellowship training) as the optimal method for preparing pharmacists as clinical/translational scientists, significant changes have occurred in the economic, professional, political, and research environments. As a result, the 2012 ACCP Research Affairs Committee was charged with reexamining the college's position on training clinical pharmacy scientists in the context of these substantial environmental changes. In this commentary, the potential impact of these changes on opportunities for pharmacists in clinical/translational research are discussed as are strategies for ACCP, colleges of pharmacy, and the profession to increase the number and impact of clinical pharmacy scientists. Failure of our profession to take advantage of these opportunities risks our ability to contribute substantively to the biomedical research enterprise and ultimately improve the pharmacotherapy of our patients.

AB - Developing clinical pharmacists' research skills and their ability to compete for extramural funding is an important component of the American College of Clinical Pharmacy's (ACCP) vision for pharmacists to play a prominent role in generating the new knowledge used to guide patient pharmacotherapy. Given the recent emphasis on clinical/translational research at the National Institutes of Health (NIH) and the key role of drug therapy in the management of many diseases, there is an unprecedented opportunity for the profession to contribute to this enterprise. A crucial question facing the profession is whether we can generate enough appropriately trained scientists to take advantage of these opportunities to generate the new knowledge to advance drug therapy. Since the 2009 publication of the ACCP Research Affairs Committee editorial recommending the Ph.D. degree (as opposed to fellowship training) as the optimal method for preparing pharmacists as clinical/translational scientists, significant changes have occurred in the economic, professional, political, and research environments. As a result, the 2012 ACCP Research Affairs Committee was charged with reexamining the college's position on training clinical pharmacy scientists in the context of these substantial environmental changes. In this commentary, the potential impact of these changes on opportunities for pharmacists in clinical/translational research are discussed as are strategies for ACCP, colleges of pharmacy, and the profession to increase the number and impact of clinical pharmacy scientists. Failure of our profession to take advantage of these opportunities risks our ability to contribute substantively to the biomedical research enterprise and ultimately improve the pharmacotherapy of our patients.

UR - http://www.scopus.com/inward/record.url?scp=84900854185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900854185&partnerID=8YFLogxK

U2 - 10.1002/phar.1348

DO - 10.1002/phar.1348

M3 - Review article

VL - 33

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 12

ER -